A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...
Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...
AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...
Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will ...
Additionally, Daiichi Sankyo and its Enhertu commercial partner AstraZeneca demonstrated excellent commercial decision-making by pursuing approval for the newly defined HER2-Low breast cancer ...
Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ET. Company Participants. Hiroyuki Okuzawa - Representative Director, Presi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback